Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.58 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.49 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28760829 | 0.85 | HSD11B1 (0.43) | OPRM1TACR3 | |
| SCHEMBL2470163 | 0.82 | TSHR (0.56) | OPRM1OPRD1OPRK1TACR3 | |
| SCHEMBL3561518 | 0.79 | AKR1C1 (0.54) | OPRM1KCNA3OPRD1OPRK1 | |
| SCHEMBL2469663 | 0.78 | NPC1 (0.52) | OPRM1KCNA3OPRD1OPRK1TACR3 | |
| SCHEMBL3563825 | 0.77 | OPRM1 (0.57) | OPRM1OPRD1 | |
| SCHEMBL3555689 | 0.77 | MEN1 (0.49) | OPRM1KCNA3OPRD1OPRK1TACR3 | |
| SCHEMBL6961790 | 0.76 | KCNA3 (0.63) | OPRM1KCNA3OPRD1OPRK1 | |
| SCHEMBL5547260 | 0.76 | UTS2R (0.50) | OPRM1KCNA3TACR3 | |
| SCHEMBL5789146 | 0.75 | HSD11B1 (0.67) | TACR3 | |
| SCHEMBL4353815 | 0.74 | HSD11B1 (0.48) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| CN-1856305-B | Pyridine derivatives as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD | 2010-04-28 | — | — | CN | disclosed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| CN-1856305-A | Pyridine derivatives and their use as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-01 | — | — | CN | disclosed |
| EP-1670470-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030209-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | OPRM1 160/4885KCNA3 281/4885OPRD1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.